Abstract
Recent years have seen an explosion in the number of publicly available x-ray crystal structures of protein kinases. These structures have provided a wealth of information on the regulatory mechanisms, conformational plasticity and drugability of this important family of enzymes. Drawing upon structural information, new insights into the development of protein kinase inhibitors are discussed including de-novo design, molecular templates for ATP competitive inhibitors and alternative mechanisms of inhibition. The highly conserved nature of the ATP binding site is of central concern to drug development and the concept of a selectivity profile has arisen with structure-based design emerging as a key tool for addressing the challenges of specificity. In addition, protein-ligand complexes, where the enzyme is in an inactive conformation, signify an alternate approach to protein kinase inhibition. The belief that an inactive kinase presents a less conserved target is reviewed using observations on the structural changes occurring during protein kinase regulation.
Keywords: x-ray crystal structure, protein kinase, atp-binding site, inhibitor
Current Medicinal Chemistry
Title: Recent Kinase and Kinase Inhibitor X-ray Structures: Mechanisms of Inhibition and Selectivity Insights
Volume: 11 Issue: 6
Author(s): M. Cherry and D. H. Williams
Affiliation:
Keywords: x-ray crystal structure, protein kinase, atp-binding site, inhibitor
Abstract: Recent years have seen an explosion in the number of publicly available x-ray crystal structures of protein kinases. These structures have provided a wealth of information on the regulatory mechanisms, conformational plasticity and drugability of this important family of enzymes. Drawing upon structural information, new insights into the development of protein kinase inhibitors are discussed including de-novo design, molecular templates for ATP competitive inhibitors and alternative mechanisms of inhibition. The highly conserved nature of the ATP binding site is of central concern to drug development and the concept of a selectivity profile has arisen with structure-based design emerging as a key tool for addressing the challenges of specificity. In addition, protein-ligand complexes, where the enzyme is in an inactive conformation, signify an alternate approach to protein kinase inhibition. The belief that an inactive kinase presents a less conserved target is reviewed using observations on the structural changes occurring during protein kinase regulation.
Export Options
About this article
Cite this article as:
Cherry M. and Williams H. D., Recent Kinase and Kinase Inhibitor X-ray Structures: Mechanisms of Inhibition and Selectivity Insights, Current Medicinal Chemistry 2004; 11 (6) . https://dx.doi.org/10.2174/0929867043455792
DOI https://dx.doi.org/10.2174/0929867043455792 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Herpesvirus / Retrovirus Chimeric Vectors
Current Gene Therapy The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Subcellular Trafficking in Rhabdovirus Infection and Immune Evasion: A Novel Target for Therapeutics
Infectious Disorders - Drug Targets Associating Paracrine Communication to Regenerative Medicine: Search Strategies & Major Trends in Scientific and Patent Production
Recent Patents on Regenerative Medicine Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design Editorial [Hot Topic: ErbB Family and Downstream Signal Transduction Pathways as Targets for Anticancer Therapy (Guest Editor: F. Caponigro)]
Current Drug Targets Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology What Western Pharmacists Need to Know About Traditional Chinese Medicine; A Canadian Perspective
Current Traditional Medicine CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Current Drug Delivery The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design